Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2300 participants.
Also called NCT07852637
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,300 participants
- Sponsor
- Registry
-
NCT07852637
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07852637. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
- Acronym
- NEXT-CAT
- Condition
- Venous Thromboembolism
- Condition
- Active Cancer
- Intervention (Drug)
- edoxaban
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Samsung Medical Center
- Collaborator
- Seoul National University Hospital
- Collaborator
- National Cancer Center, Korea
- Collaborator
- Seoul St. Mary's Hospital
- Collaborator
- Dong-A University Hospital
- Collaborator
- Chonnam National University Hospital
- Collaborator
- Korea University Anam Hospital
- Collaborator
- Inje University Ilsan Paik Hospital
- Collaborator
- Konkuk University Hospital
- Collaborator
- Kangbuk Samsung Hospital, Sungkyunkwan University
- Collaborator
- Chung-Ang University Gwangmyeong Hospital
- Collaborator
- Chonbuk National University Hospital
Record details
- Record id
cardio:ct-nct07852637- Content hash
4ef8865500e8ee38c727d1a3df9c1820db5cdf909b27a4b850f6c5b3aea8b917